B3GALNT2

beta-1,3-N-acetylgalactosaminyltransferase 2, the group of Beta 3-glycosyltransferases

Basic information

Region (hg38): 1:235447190-235504452

Links

ENSG00000162885NCBI:148789OMIM:610194HGNC:28596Uniprot:Q8NCR0AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

  • muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 11 (Strong), mode of inheritance: AR
  • muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 11 (Strong), mode of inheritance: AR
  • muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 11 (Moderate), mode of inheritance: AR
  • muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 11 (Strong), mode of inheritance: AR
  • muscular dystrophy-dystroglycanopathy, type A (Supportive), mode of inheritance: AR
  • muscle-eye-brain disease (Supportive), mode of inheritance: AR
  • autosomal recessive non-syndromic intellectual disability (Supportive), mode of inheritance: AR
  • intellectual disability (Limited), mode of inheritance: AR

Clinical Genomic Database

Source: CGD

ConditionInheritanceIntervention CategoriesIntervention/Rationale Manifestation CategoriesReferences
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 11ARGeneralGenetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testingCardiovascular; Musculoskeletal; Neurologic; Ophthalmologic23453667

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the B3GALNT2 gene.

  • Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 11 (23 variants)
  • not provided (2 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the B3GALNT2 gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
1
clinvar
94
clinvar
95
missense
2
clinvar
183
clinvar
2
clinvar
3
clinvar
190
nonsense
8
clinvar
3
clinvar
2
clinvar
1
clinvar
14
start loss
1
clinvar
1
frameshift
12
clinvar
1
clinvar
3
clinvar
1
clinvar
17
inframe indel
1
clinvar
7
clinvar
8
splice donor/acceptor (+/-2bp)
3
clinvar
9
clinvar
12
splice region
15
16
1
32
non coding
19
clinvar
98
clinvar
36
clinvar
153
Total 23 16 216 196 39

Highest pathogenic variant AF is 0.0000197

Variants in B3GALNT2

This is a list of pathogenic ClinVar variants found in the B3GALNT2 region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
1-235448125-G-A Likely benign (Jul 09, 2018)1211214
1-235448206-A-C Likely benign (Oct 06, 2019)1186898
1-235448220-CA-C Benign (Oct 06, 2019)1242668
1-235448220-C-CA Benign (Oct 05, 2019)1280812
1-235448220-C-CAA Benign (Oct 07, 2019)1250633
1-235448220-C-CAAA Benign (Oct 07, 2019)1233617
1-235448329-C-A Likely benign (Jul 07, 2023)2737570
1-235448330-T-G Likely benign (Jan 24, 2023)2831779
1-235448331-T-G Likely benign (Jul 29, 2023)2839906
1-235448332-T-C Likely benign (Aug 31, 2023)3003452
1-235448335-T-C Hypoparathyroidism-retardation-dysmorphism syndrome Benign/Likely benign (Jan 31, 2024)875575
1-235448337-G-A Likely benign (Dec 15, 2023)1991247
1-235448341-T-TTTGA Likely benign (Oct 05, 2023)3016374
1-235448350-C-T Likely benign (Oct 22, 2023)2782745
1-235448358-C-CAATTCAAAAGGTGAAGGGATTGCTG Encephalopathy, progressive, with amyotrophy and optic atrophy Uncertain significance (May 26, 2020)1806069
1-235448365-A-G Likely benign (Dec 27, 2022)2801228
1-235448368-G-A Likely benign (Jun 14, 2022)1969090
1-235448371-G-GAAGGGATTGCTGTCACGTCTTCTCAAAGTTCCT Inborn genetic diseases Uncertain significance (Sep 20, 2022)1491529
1-235448374-G-A Likely benign (Sep 27, 2023)2782506
1-235448377-A-T Likely benign (May 19, 2023)2790629
1-235448378-T-C Likely benign (Jan 21, 2024)1959485
1-235448382-T-C Uncertain significance (Jun 11, 2022)2004825
1-235448387-C-T Uncertain significance (Jun 04, 2022)2187208
1-235448388-G-A Inborn genetic diseases Uncertain significance (Jul 12, 2022)1471918
1-235448392-T-C Likely benign (Dec 21, 2022)2822862

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
B3GALNT2protein_codingprotein_codingENST00000366600 1254544
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
2.81e-70.98212563501131257480.000449
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense0.9512222660.8360.00001443252
Missense in Polyphen5362.7140.84511732
Synonymous0.716951040.9110.00000631961
Loss of Function2.201527.40.5470.00000147309

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.0004770.000477
Ashkenazi Jewish0.0009930.000993
East Asian0.0006000.000598
Finnish0.0001390.000139
European (Non-Finnish)0.0006600.000642
Middle Eastern0.0006000.000598
South Asian0.00006540.0000653
Other0.0001630.000163

dbNSFP

Source: dbNSFP

Function
FUNCTION: Beta-1,3-N-acetylgalactosaminyltransferase that synthesizes a unique carbohydrate structure, GalNAc-beta-1- 3GlcNAc, on N- and O-glycans. Has no galactose nor galactosaminyl transferase activity toward any acceptor substrate. Involved in alpha-dystroglycan (DAG1) glycosylation: acts coordinately with GTDC2/POMGnT2 to synthesize a GalNAc-beta3-GlcNAc-beta-terminus at the 4-position of protein O-mannose in the biosynthesis of the phosphorylated O-mannosyl trisaccharide (N-acetylgalactosamine- beta-3-N-acetylglucosamine-beta-4-(phosphate-6-)mannose), a carbohydrate structure present in alpha-dystroglycan, which is required for binding laminin G-like domain-containing extracellular proteins with high affinity. {ECO:0000269|PubMed:14724282, ECO:0000269|PubMed:23453667, ECO:0000269|PubMed:23929950}.;
Disease
DISEASE: Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A11 (MDDGA11) [MIM:615181]: An autosomal recessive disorder characterized by congenital muscular dystrophy associated with cobblestone lissencephaly and other brain anomalies, eye malformations, profound mental retardation, and death usually in the first years of life. Included diseases are the more severe Walker-Warburg syndrome and the slightly less severe muscle-eye-brain disease. {ECO:0000269|PubMed:23453667}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Pathway
Mannose type O-glycan biosynthesis - Homo sapiens (human);Post-translational protein modification;Metabolism of proteins;O-linked glycosylation (Consensus)

Intolerance Scores

loftool
0.850
rvis_EVS
-0.71
rvis_percentile_EVS
14.5

Haploinsufficiency Scores

pHI
0.0926
hipred
N
hipred_score
0.333
ghis
0.550

Essentials

essential_gene_CRISPR
N
essential_gene_CRISPR2
N
essential_gene_gene_trap
N
gene_indispensability_pred
N
gene_indispensability_score
0.155

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium

Mouse Genome Informatics

Gene name
B3galnt2
Phenotype

Zebrafish Information Network

Gene name
b3galnt2
Affected structure
skeletal muscle cell
Phenotype tag
abnormal
Phenotype quality
disorganized

Gene ontology

Biological process
protein glycosylation;protein O-linked glycosylation
Cellular component
Golgi membrane;endoplasmic reticulum;endoplasmic reticulum membrane;Golgi apparatus;integral component of membrane
Molecular function
acetylglucosaminyltransferase activity;acetylgalactosaminyltransferase activity;galactosyltransferase activity